Abstract:Abstract Introduction: It has recently been shown that the population of CD45+ Col1+ CXCR4+ (characteristic fibrocyte markers) cells increases in the bone marrow after bleomycin-induced lung injury. But little is known about their existence in primary or secondary myelofibrosis. Questions also remain about the exact origin of fibrocytes and how their development/differentiation is altered in response to tissue damage. Fibrocytes are believed to be a bone marrow-derived cell type, differentiated from monocytes, with essential roles in both normal tissue repair and multiple fibrotic diseases. Fibrocytes are unique in that they express both stromal and hematopoietic markers. Fibrocytes have been isolated and cultured from murine and human blood PMBCs, however, this method yields a low number of cells per animal. The murine splenic monocyte reservoir has also been shown to be able to give rise to fibrocyte cultures. Methods: Long bones (humeri and femurs) were obtained from adult C57BL/6J mice ± 14 Gy and Gata-1low C57Bl/6J mice bred with CD1 mice. Bones were aseptically flushed with sterile PBS. Collected bone marrow was passed through a 22 gauge needle to further dissociate the cells. Cells were centrifuged at 300 x g for 10 min at room temperature. Cells were washed and red blood cells were lysed. After a wash cells were resuspended in supplemented Fibrolife media (10 mM, 2 x non-essential amino acids, 2 mM sodium pyruvate, 4 mM glutamine, 100 U/ml penicillin, 100 g/ml streptomycin, 2× ITS-3, and 50 μM 2-mercaptoethanol) and plated at 1.25x106 cells/mL. Cells differentiated for 7-10 days before analysis. Immunocytochemical staining and qPCR analysis was performed using standard methods. Results: Using this new method to isolate fibrocytes from total murine bone marrow, we found that Fibrocytes differentiated as early as 5 days in serum-free media. In addition to exhibiting the characteristic spindle shape morphology, cultured fibrocytes also expressed both hematopoietic (CD45) and stromal markers (collagen I). Importantly, these cells were negative for the fibroblast specific marker fibronectin, confirming that these cells were not fibroblasts. Cultured fibrocytes also appeared to be terminally differentiated, as they could not be passaged. Bone marrow-derived fibrocytes were found to upregulate collagen I in response to TGFβ treatment, mirroring the response reported in blood-derived fibrocytes in lung fibrosis. We further identified fibrocytes from the peripheral blood of heterozygous Gata-1low mice, which displayed myelofibrosis. Irradiation of shielded mice with 14 Gy resulted in myelofibrosis by 60 days (as opposed to ~12 months in Gata-1low mice). Furthermore, there was associated increased TGFbeta production. This correlated with a marked increase in fibrocytes. Conclusions: Our new culturing method will further facilitate the study of fibrocyte differentiation and response to both pro- and anti-inflammatory signals. We are currently utilizing flow cytometry to characterize fibrocyte kinetics and to quantify these cells in mice and patients with myelofibrosis. Our data also suggest that fibrocytes may play a contributing role to myelofibrosis in part through TGFb pathways. We have also developed an radiation-induced model of myelofibrosis with characteristic TGFbeta and circulating fibrocytes. Because myelofibrosis occurs in a much shorter time period, this model may be useful to more rapidly evaluate novel anti-fibrotic therapies. This work was supported by a Translational Award from the Leukemia and Lymphoma Society. Disclosures No relevant conflicts of interest to declare.

Therapeutic activity of GARP:TGF-β1 blockade in murine primary myelofibrosis

Selective targeting of GARP-LTGFβ axis in the tumor microenvironment augments PD-1 blockade via enhancing CD8+ T cell antitumor immunity

Immunoregulatory functions and the therapeutic implications of GARP-TGF-β in inflammation and cancer

Targeting exhausted cytotoxic T cells through CTLA-4 inhibition promotes elimination of neoplastic cells in human myelofibrosis xenografts

Proteomic screening identifies PF4/Cxcl4 as a critical driver of myelofibrosis

Suppression of lysosome metabolism-meditated GARP/TGF-β1 complexes specifically depletes regulatory T cells to inhibit breast cancer metastasis

TGFβ1 neutralization displays therapeutic efficacy through both an immunomodulatory and a non-immune tumor-intrinsic mechanism

A novel GARP humanized mouse model for efficacy assessment of GARP-targeting therapies

CXCL8 and its cognate receptors CXCR1/CXCR2 in primary myelofibrosis

The Variation in the Traits Ameliorated by Inhibitors of JAK1/2, TGF-β, P-Selectin, and CXCR1/CXCR2 in the Gata1low Model Suggests That Myelofibrosis Should Be Treated by These Drugs in Combination

Analysis of the Biological Properties of Blood Plasma Protein with GcMAF Functional Activity

Abstract 2727: Pre-clinical development of a novel anti-GPRC5D inducing potent anti-tumor effect through enhanced antibody-dependent cell-mediated cytotoxicity (ADCC) for multiple myeloma

A CXCR4 partial agonist improves immunotherapy by targeting polymorphonuclear myeloid-derived suppressor cells and cancer-driven granulopoiesis

Inhibition of RhoA-mediated secretory autophagy in megakaryocytes mitigates myelofibrosis in mice

Circulating Polymorphonuclear Myeloid-Derived Suppressor Cells (PMN-MDSCs) Have a Biological Role in Patients with Primary Myelofibrosis

Abstract 3628: Combined mek and jak inhibition in vitro is an effective strategy in overcoming jak inhibitor resistance in primary myelofibrosis (PMF)

Abstract 172: Targeting the poliovirus receptor to activate T cells and induce myeloid-derived suppressor cells to differentiate to M1-like macrophages via the IFNγ-pSTAT1-IRF8 axis in cancer therapy

Targeting RGMb interactions: Discovery and preclinical characterization of potent anti-RGMb antibodies blocking multiple ligand bindings

Supplementary Methods from Monoclonal Antibody Against Cell Surface GRP78 As a Novel Agent in Suppressing PI3K/AKT Signaling, Tumor Growth, and Metastasis

Identification of Bone Marrow-Derived and Circulating Fibrocytes in Gata1low Mice with Myelofibrosis

GARP promotes the proliferation and therapeutic resistance of bone sarcoma cancer cells through the activation of TGF-β